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Postoperative pain is a nociceptive type of pain that
develops as a result of tissue damage after surgical
trauma, and is accompanied by central and peripheral
sensitization. Approximately, 30–75% of patients expe-
rience moderate to severe pain in the postoperative
period [1,2]. Inadequate analgesia in this period may
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Pain intensity may be high in the postoperative period after spinal vertebral surgery. The aim of
the study was to compare the effectiveness and cost of patient controlled analgesia (PCA) with
tramadol versus low dose tramadol-paracetamol on postoperative pain. A total of 60 patients
were randomly divided into two groups. One group received 1.5 mg/kg tramadol (Group T)
while the other group received 0.75 mg/kg tramadol plus 1 g of paracetamol (Group P) intra-
venously via a PCA device immediately after surgery and the patients were transferred to a
recovery room, Tramadol was continuously infused at a rate of 0.5 mL/h in both groups, at a
dose of 10 mg/mL in Group T and 5 mg/mL in Group P. The bolus and infusion programs were
adjusted to administer a 1 mL bolus dose of tramadol with a lock time of 10 minutes. In Group P,
1 g of paracetamol was injected intravenously every 6 hours. The four-point nausea scale,
numeric rating scale for pain assessment, Ramsey sedation scale, blood pressure, heart rate, res-
piration rate, peripheral oxygen saturation values and side effects were recorded at 0, 15 and 30
minutes, and at 1, 2, 4, 6, 12, 18 and 24 hours. The time to reach an Aldrete score of 9 was also
recorded. A cost analysis for both groups was performed. In Group P, the numeric rating scale
scores were significantly lower than that in Group T at 0 and 15 minutes. The number of side
effects, additional analgesic requirement and the total dose of tramadol were lower in Group P
than in Group T. However, the total cost of postoperative analgesics was significantly higher in
Group P than in Group T (p < 0.001). We conclude that PCA using tramadol-paracetamol could be
used safely for postoperative pain relief after spinal vertebral surgery, although at a higher cost
than with tramadol alone.
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lead to functional deterioration caused by the patho-
physiology of acute pain, and may trigger a sensitiza-
tion process in the central and peripheral nervous
systems, leading to chronic pain [1–5]. This ultimately
increases the cost and the length of stay in a hospital
[6,7]. Patient controlled analgesia (PCA) allows pa-
tients to administer their own analgesic medications
when necessary. This reduces their anxiety and stress,
both of which are major factors associated with post-
operative pain [8].
The ideal analgesic agent used in PCA should have
a rapid onset and a moderate duration. Furthermore,
the agent should be free of side effects such as a ceil-
ing dose, nausea, vomiting, respiratory depression and
intestinal motility disorder. Opioids are commonly
used as analgesics in intravenous (IV) PCA [9]. Non-
steroidal anti-inflammatory drugs (NSAIDs) are also
commonly used for postoperative analgesia to avoid
the side effects of opioids [10,11].
The aims of this study were to identify the effects
of IV paracetamol on PCA tramadol use after spinal
vertebral surgery and estimate the costs of the two
types of treatment.
METHODS
This prospective, randomized and controlled study
was conducted after obtaining the approval of the
Medical School Ethics Committee and informed con-
sent from the patients. 
A total of 60 patients who were scheduled for spi-
nal vertebral surgery, and who were classified in the
American Society of Anesthesiologists risk group I–II
were admitted to the study. Their ages ranged from
18 to 60 years. Patients meeting any of the following
criteria were excluded: (1) use of analgesics during the
24-hour period before surgery; (2) known allergy to
any of the study drugs; (3) inability to use the PCA de-
vice due to lack of communication or muscle strength;
(4) severe cardiopulmonary, renal or liver disease, mor-
bid obesity (body mass index >30 kg/m2), or history of
postoperative nausea and vomiting; (5) history of mi-
graines; (6) current pregnancy, (7) history of alcohol
abuse and convulsion anamnesis; (8) use of mono-
amine oxidase or serotonin reuptake inhibitors; or 
(9) history of complications during and after surgery.
In the preanesthetic evaluation, all patients were
informed about the anesthesia method to be used.
They were also trained on how to use the patient con-
trolled analgesia device (Pain Management Provider,
Abbott Laboratories, Chicago, IL, USA) and the 10-
point numeric rating scale. We also collected verbal
and written consent at this time. Thirty minutes before
the patients were taken to the operation room, they
were administered with 0.01 mg/kg atropine sulfate
and 0.1 mg/kg midazolam intramuscularly.
In the operating room, patients were administered
with 2 L/min oxygen (O2) via a nasal cannula. Elec-
trocardiograph, heart rate (HR), mean blood pressure
(MBP) and peripheral O2 saturation (SpO2) were mon-
itored using a Datex Ohmeda Cardiocap 5 (General
Electric, Helsinki, Finland). Anesthesia was induced by
2 mg/kg propofol and 0.1 mg/kg vecuronium bro-
mide. For analgesia, 0.05–2 μg/kg/min remifentanil
hydrochloride was infused IV. Anesthesia was main-
tained with 50% O2, 50% air and 1–1.5 minimum alve-
olar concentration (MAC) desflurane. Muscle relaxation
was maintained by administering 0.03 mg/kg vecuro-
nium bromide as needed.
In the study, hypotension (> 20% from the baseline
systolic arterial blood pressure) was treated with IV
boluses of 5 mg ephedrine repeated every 3 minutes,
and bradycardia (heart rate <55 bpm) treated with
atrophine 0.5/mg if occurs.
Patients were randomly divided into two groups
using a random samples table. Group T received
1.5mg/kg tramadol (100mg/mL; Contramal ampoule,
Abdi Ibrahim, Istanbul, Turkey) via one arm after
remifentanil infusion via another arm, and Group P
received 0.75 mg/kg tramadol plus 1 g paracetamol
(Perfalgan®; Bristol-Myers Squibb, Istanbul, Turkey)
intravenously via one arm, 15 minutes after stopping
remifentanil infusion via another arm. Control values
were recorded before the administration of the study
drugs. The patients’ vital signs were also taken and
recorded afterwards. The duration of the surgical pro-
cedure and the total amount of remifentanil adminis-
tered were recorded. Muscle relaxation was reversed
by 0.05 mg/kg neostigmine and 0.01 mg/kg atropine.
The PCA device was inserted immediately after
the patients were transferred to the postanesthesia
recovery room and extubation. The tramadol dose for
Group T was 10 mg/mL and continuous infusion was
given at 0.5 mL/hr. In Group P, the tramadol dose
was 5 mg/mL and continuous infusion was given 
at 0.5 mL/hr. In both groups, the bolus dose was
1 mL and the lockout time for the bolus and infusion
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program was 10 minutes. In Group P, 1 g of paraceta-
mol was administered intravenously over 15 minutes
every 6 hours. The 4-hr dose limit was 300 mg.
In the recovery room, the patients’ vital signs were
monitored by Criticare 1100 (Criticare Systems Inc.,
Waukesha, WI, USA). The following parameters were
recorded immediately after the patients were taken
to the recovery room at 0, 15 and 30 minutes and at 1, 2,
4, 6, 12, 18 and 24 hours after commencing PCA: four-
point nausea vomiting scale, numerical rating scale
(NRS) for pain level, Ramsey sedation scale (1 = anx-
ious, restless or both; 2 = cooperative, orientated and
tranquil; 3 = responding to commands; 4 = brisk res-
ponse to stimulus; 5 = sluggish response to stimulus;
6 = no response to stimulus), Aldrete score (Activity:
voluntary movement of all limbs to command = 2
points, voluntary movement of two extremities to
command = 1 point, unable to move = 0 points; Respi-
ration: breathe deeply and cough = 2 points, dyspnea
or hypoventilation = 1 point, apnea = 0 points; Circu-
lation: BP ± 20 mmHg of the preanesthesia level = 2
points, BP±20–50 mmHg of the preanesthesia level= 1
point, BP >±50mmHg of preanesthesia level=0 points;
Consciousness: fully awake = 2 points, arousable = 1
point, unresponsive = 0 points; Color: pink = 2 points,
pale or blotchy = 1 point, cyanotic = 0 points), time
needed to reach an Aldrete score of 9, MBP, HR, res-
piration rates, SpO2 values and side effects.
The following additional drugs were allowed:
1 mg/kg pethidine hydrochloride intramuscularly
(50 mg/mL Aldolan ampoule) in the event of inade-
quate analgesia; 10 mg metoclopramide IV for nausea
and vomiting; 45.5 mg pheniramine maleate for itch-
ing; an increased IV dose of naloxone for respiratory
depression (< 10 breaths-per-min); and 5 mg of dia-
zepam for convulsion. After 24 hours, the doses, total
tramadol dose were recorded from the memory of the
PCA device and the satisfaction score were recorded.
To estimate the total cost, we included the unit costs
of tramadol, paracetamol, metoclopramide and pethi-
dine. As of November 2009, the prices of one ampoule
of tramadol (100 mg/mL), one flacon of paracetamol
(1 g), one ampoule of metoclopramide and pethidine
were 1.45 euro (€), 2.57€, 0.4€ and 0.51€, respectively.
A sample size of 56 patients was chosen to detect
the difference of one unit on the NRS, with an α error
=0.05 and power at 80% [12]. Thus the 60 patients were
enrolled in this study and they were allocated into
two equal groups .
Statistical analyses were performed using SPSS
version 10.0 (SPSS Inc., Chicago, IL, USA). Student’s 
t test was used to compare age, weight, surgical dura-
tion, MBP, HR, respiration rate, SpO2, NRS, Aldrete
score, time to reach an Aldrete score of 9, total remifen-
tanil and tramadol dose and the cost of administered
drugs. American Society of Anesthesiologists risk
group, sex, side effects, need for additional drugs and
sedation level were compared using χ2 tests.
RESULTS
There was no significant difference between the groups
with respect to the patients’ demographic character-
istics, American Society of Anesthesiologists risk group
and surgical duration (Table 1). Similarly, there were
no differences between the groups in terms of MBP,
HR and SpO2 values (p > 0.05) (Table 2).
The NRS values at 0 and 15 minutes were signifi-
cantly higher in Group T than in Group P (p < 0.05)
(Figure 1). There were no significant differences be-
tween the two groups in terms of Ramsey sedation
scores, Aldrete scores or the time needed to reach
Aldrete score of 9 (p > 0.05) (Table 3).
A comparison of the nausea scores revealed that
they were significantly higher in Group T than in
Table 1. Demographic and clinical characteristics of patients administered with tramadol or tramadol-paracetamol
Tramadol group (n = 30) Tramadol-paracetamol p
group (n = 30)
Age (yr) 47.7 ± 8.7 44.5 ± 12.1 NS
Weight (kg) 78.2 ± 6.2 76.3 ± 6.9 NS
Sex, M/F 11/19 8/22 NS
ASA risk group (I/II) 17/13 18/12 NS
Duration of surgery (min) 174.2 ± 40.4 163.3 ± 38.1 NS
Number of laminectomies 2.9 ± 0.6 2.7 ± 0.7 NS
*Data presented as mean ± standard deviation or n (%). ASA = American Society of Anesthesiologists; NS = not significant.
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Table 2. Changes in hemodynamic parameters in patients administered with tramadol or tramadol-paracetamol*
MBP (mmHg) HR (beats/min) SpO2 (%)
Tramadol 
Tramadol-
Tramadol 
Tramadol-
Tramadol 
Tramadol-
paracetamol paracetamol paracetamol 
group (n = 30)
group (n = 30) group (n = 30) group (n = 30) group (n = 30) group (n = 30)
Control 87.3 ± 17.6 89.1 ± 10.5 76.0 ± 6.5 74.3 ± 7.9 99.1 ± 0.7 99.5 ± 0.6
After ind 89.2 ± 8.9 84.9 ± 8.7 74.8 ± 6.7 72.7 ± 8.8 98.9 ± 0.9 99.4 ± 0.7
0 min 87.8 ± 9.8 89.3 ± 10.5 80.8 ± 6.6 77.5 ± 7.0 97.8 ± 0.7 98.3 ± 0.8
15 min 87.6 ± 9.4 89.9 ± 11.0 77.6 ± 8.5 77.2 ± 9.8 97.3 ± 0.9 98.0 ± 1.1
30 min 90.4 ± 9.4 90.5 ± 11.8 77.9 ± 7.1 77.8 ± 10.2 97.3 ± 1.1 97.9 ± 0.9
1 hr 87.7 ± 9.0 91.1 ± 11.9 72.9 ± 6.7 74.8 ± 8.9 97.3 ± 0.9 97.5 ± 1.0
2 hr 88.4 ± 9.0 89.7 ± 9.7 75.0 ± 9.1 77.0 ± 9.3 97.2 ± 0.9 97.4 ± 0.9
4 hr 86.8 ± 10.2 93.2 ± 11.1 74.8 ± 9.2 74.3 ± 6.8 97.1 ± 1.3 97.5 ± 1.0
6 hr 92.4 ± 8.8 90.5 ± 11.8 75.5 ± 9.4 76.1 ± 9.5 97.3 ± 0.9 97.6 ± 0.8
12 hr 90.7 ± 7.7 91.5 ± 10.3 76.9 ± 7.9 76.1 ± 9.9 96.7 ± 1.1 97.4 ± 0.9
24 hr 92.6 ± 9.8 89.1 ± 8.8 75.7 ± 7.9 76.0 ± 7.1 97.2 ± 0.9 97.5 ± 0.7
*Data presented as mean ± standard deviation. MBP = mean blood pressure; HR = heart rate; SpO2 = peripheral oxygen saturation;
After ind = after analgesia induction.
Figure 1. Changes in the numeric rating scale in patients
administered with tramadol or tramadol-paracetamol. *p < 0.05.
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Group P at 0, 15 and 30 minutes, and at 1, 4, 6 and 12
hours (p < 0.05) (Figure 2). All subjects who expe-
rienced severe nausea responded to treatment. In
Group T, vomiting occurred at 0 minutes in one pa-
tient, at 15 minutes in five patients, at 30 minutes in
five patients, 1 hour in two patients, at 4 and 6 hours in
one patient each and at 12 hours in two patients. On
the other hand, in Group P, vomiting occurred at 
0 minutes in two patients, at 15 minutes in one patient
and at 4 hours in one patient. The rate of vomiting was
significantly lower in Group P than Group T at 30 min-
utes (p=0.02). There were no stastical difference in rate
of vomiting in other time points between two groups,
and no subject suffered from persistent vomiting.
In Group T, perspiration was observed at 1 and 2
hours in two patients each, and at 4, 6 and 12 hours in
one patient each. There was not perspiration in any
patient in Group P. The rate of perspiration was not
significantly different between the two groups. In addi-
tion, no subject suffered from respiratory depression,
bradycardia or hypotension.
None of the subjects in either group needed addi-
tional drugs such as ephedrine, atropine and nalox-
one after the control or infusion of the study drugs.
The total doses of pethidine hydrochloride (p = 0.006)
and metoclopramide (p < 0.001) used in Group T were
significantly higher than those used in Group P (Table
4). The mean dose of remifentanil used during the
operation was not significantly different between the
two groups (Table 4). The mean required and admin-
istered amounts of tramadol, and the total dose of
tramadol were significantly higher in Group T than
in Group P (p < 0.01) (Table 4).
The total cost of tramadol, metoclopramide and
pethidine was significantly higher in Group T than in
Group P (4.5 ± 0.5€ vs. 2.3 ± 0.4€; p < 0.001). However,
because the mean cost of paracetamol was 10.3€ per
patient in Group P (p < 0.001 vs. Group T), the total
cost of drugs, including paracetamol, was significantly
higher in Group P than in Group T (12.6 ± 0.4€ vs.
4.5 ± 0.5€; p < 0.001).
In Group T, the satisfaction score was rated as
good by four (13.3%) patients and as very good by 26
(86.7%) patients. In Group P, the satisfaction score
was rated as good by two (6.7%) patients and as very
good by 28 (93.3%) patients. There was no significant
different between the two groups in terms of the gen-
eral satisfaction scores (p > 0.05).
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DISCUSSION
Effective postoperative analgesia prevents many of
the negative effects associated with pain. Thus, all
authorities agree that postoperative pain needs to be
managed effectively [13]. McHugh et al [14] reported
that approximately 82% of patients undergoing day
surgery leave the operating room reporting pain.
Studies have shown the many advantages of IV
patient controlled postoperative analgesia. The PCA
method minimizes fluctuations in plasma drug con-
centrations that would otherwise have an adverse
effect on the effectiveness of postoperative analgesic
agents and exacerbate their side effects. Thus, ade-
quate analgesia can be provided with smaller drug
doses and fewer side effects [15]. The ideal postoper-
ative analgesic treatment should have a rapid onset
of effect, low incidence of side effects and a minimal
effect on major organs. The use of opioids in the treat-
ment of postoperative pain dates back to the early
days of modern surgery. However, opioids have dose
dependent side effects, which limit their use and may
prevent adequate pain control [16].
Perioperative paracetamol and other NSAIDs re-
duce the dose needed for opioids and the incidence
of side effects [17–19]. Although, non-opiate drugs have
less analgesic effect than opioids, they may have bet-
ter outcomes and may increase the effectiveness of
opioids when used for somatic-visceral pain [20].
Because of their synergistic effects, adjuvant drugs in
combination with opioids decrease the incidence of
side effects associated with opioids [6]. NSAIDs con-
stitute one part of a multi-factorial approach for pain
control. NSAIDs primarily inhibit prostaglandin syn-
thesis at peripheral sites of inflammation. In addition
they may exert their analgesic effect by acting within
the central nervous system (CNS). The central effect
of NSAIDs increases their peripheral mechanism of
action, due to interference with the formation of pros-
taglandin within the CNS. The central mechanism may
be mediated by endogen opioids peptides or block-
ade of the release of serotonin. Inhibition of excita-
tory amino acids of NMDA activation has also been
proposed [21]. Besides the arachidonic acid cascade
in peripheral tissue is affected by NSAIDs, their use
in combination with opioids is quite effective in spe-
cific receptors due to their central effect [22]. It has
been shown that paracetamol in combination with
tramadol is more effective than the use either drug
alone, because their mechanisms of action and phar-
macokinetics complement each other [22,23].
The onset of analgesia is faster with IV than oral
paracetamol and the time to reach maximum pain
relief is shorter. Thus, IV paracetamol is more effective
in reducing pain intensity within the 1st hour of treat-
ment [24]. Hence, IV paracetamol was preferred in
this study because of these characteristics.
In a study to determine whether the addition of IV
paracetamol would reduce daily morphine consump-
tion in patients with postoperative pain after ortho-
pedic surgery, 60 patients were randomly selected to
Table 3. Changes in Ramsey and Aldrete scores in patients administered with tramadol or tramadol-paracetamol*
Aldrete scores Ramsey scores
Tramadol 
Tramadol-
Tramadol 
Tramadol-
paracetamol paracetamol 
group (n = 30)
group (n = 30) group (n = 30) group (n = 30)
0 min 7.8 ± 0.4 7.8 ± 0.3 2.5 ± 0.5 2.3 ± 0.4
15 min 9.7 ± 0.4 9.8 ± 0.4 2.1 ± 0.3 2.0 ± 0.2
30 min 10.0 ± 0.0 10.0 ± 0.0 2.0 ± 0.2 2.0 ± 0.0
60 min 10.0 ± 0.0 10.0 ± 0.0 2.0 ± 0.2 2.0 ± 0.0
Time to Aldrete score of 9 (min) 7.3 ± 1.3 5.9 ± 1.3
*Data presented as mean ± standard deviation.
Figure 2. Changes in the nausea score in patients administered
with tramadol or tramadol-paracetamol. *p < 0.05.
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receive IV paracetamol or placebo [25]. All patients
were given 15-minute IV infusions every 6 hours after
surgery. All patients received morphine via PCA (1 mg
bolus; 15-minute lockout interval; basal rate, 0.5 mg/
hr). The total morphine dose per 24 hours and the
number of bolus doses were determined. In that study,
morphine consumption was significantly in the IV
paracetamol group, and the number of bolus doses
per 24 hours decreased by 37% [25] versus morphine
alone.
Another study was conducted to assess the anal-
gesic effectiveness and the incidence of side effects
for the addition of IV paracetamol or placebo to mor-
phine in patients who underwent spinal fusion sur-
gery [26]. In that study, both groups administered
morphine PCA morphine, and reduction in morphine
dose was 46%. The sedation level was mild for all
patients; however, 3 days after surgery, the sedation
level was significantly lower in the IV paracetamol
group than the placebo group. Thus, adding IV parac-
etamol to opioids in patients suffering from orthope-
dic postoperative pain was found to be safe and
effective, and reduced the required opioid dose [26].
In a study [17] comparing 1 g IV paracetamol, 2 g
propacetamol and placebo on postoperative pain after
major orthopedic surgery (knee replacement surgery)
in 151 patients, the initial drug request time was sig-
nificantly longer in the group given the two active
drugs. Evaluation of the 24-hour pain intensity revealed
that the pain scores were significantly lower in this
group in comparison with the other group. This study
showed that IV paracetamol is efficient and safe for
pain relief after knee replacement surgery [17].
Another study compared paracetamol, paraceta-
mol-tramadol and paracetamol-nalbuphine for anal-
gesia after supratentorial craniotomy performed under
propofol-remifentanil anesthesia. One hour before
surgery was completed, all subjects were administered
IV with 30 mg/kg paracetamol, followed by 30 mg/kg
every six hours. The paracetamol-tramadol group
was also given 1.5 mg/kg tramadol at the same time.
The authors concluded that paracetamol alone was
inadequate to suppress craniotomy pain, and that
tramadol or nalbuphine were needed in combination
with paracetamol for adequate analgesia [27].
Similarly, in the present study, the NRS scores re-
ported by patients in Group P were significantly
lower at 0 and 15 minutes than those in Group T. The
NRS scores remained lower at all times in Group P
than in Group T. It was found that the tramadol de-
mand and administration amounts, and the total tra-
madol dose were lower in Group P than in Group T. In
this study, we allowed the use pethidine in both
groups to provide additional analgesia for patients
with a NRS score exceeding 4. In fact, the mean pethi-
dine dose was significantly lower in Group P than in
Group T.
Although tramadol has minimal cardiovascular
affects, it has been reported to cause a slight but clini-
cally insignificant increase in HR and blood pressure
[28]. On the other hand, paracetamol does not affect
the cardiovascular system at therapeutic doses [29].
In the present study, we found no significant differ-
ences between the two groups in terms of systolic,
diastolic and MBP, and HR at any time-point. The
decrease in MBP and HR values did not exceed 20%
and no additional treatment was deemed necessary
in any subject.
Previous studies of IV PCA, particularly using opi-
oids, have reported low rates of the most feared side
effect, respiratory depression [30–32]. Tramadol has
been reported to provide adequate analgesia without
causing changes in the respiratory rate, SpO2 and
blood gases, or causing hypoxia, and is thought to
Table 4. Use of total metoclopramide, pethidine, remifentanil and tramadol doses*
Tramadol Tramadol-paracetamol 
p
group (n = 30) group (n = 30)
Metoclopramide (mg) 5.7 ± 5.0 1.3 ± 3.4 < 0.001
Pethidine (mg) 45.4 ± 33.8 20.8 ± 32.8 0.006
Remifentanil (μg) 1,207.9 ± 340.1 1,113.6 ± 403.5 –
Required amount of tramadol (mg) 67.7 ± 25.9 47.7 ± 16.5 0.010
Administered amount of tramadol (mg) 62.8 ± 23.5 39.2 ± 12.8 0.010
Total dose tramadol (mg) 276.0 ± 45.1 153.0 ± 15.6 < 0.001
*Data presented as mean ± standard deviation.
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have a clear advantage over opioids [28,30,32]. Un-
like opioids, tramadol is not related to central side
effects that occur as a result of paracetamol binding
to receptors in the CNS. Hence, tramadol is not asso-
ciated with nausea, vomiting, sedation or respiratory
depression [28,33,34]. The respiratory rates were
recorded in this study because they could indicate
the presence of respiratory depression as a result of
the drugs used. However, none of the subjects devel-
oped a respiratory rate below 10 breaths/min, which
could indicate respiratory depression. Furthermore,
the respiratory rates and SpO2 values were not signif-
icantly different between the two groups. We did not
expect any instances of respiratory depression at the
doses of tramadol used in this study.
Side effects of tramadol have been reported to in-
clude nausea, vomiting, perspiration, headache, fa-
tigue, dryness of the mouth, and urinary retention
[28]. The most commonly observed side effects of tra-
madol are nausea and vomiting, which are caused by
chemoreceptor trigger zone stimulation [28]. Although
paracetamol may cause nausea, vomiting, loss of ap-
petite, stomach ache and hypoglycemic coma at high
doses, it is well-tolerated at therapeutic doses [34]. In
our study, the nausea scores were significantly higher
in Group T than in Group P, which is consistent with
findings in other studies. Accordingly, the mean dose
of metoclopramide, an antiemetic, was significantly
higher in Group T than that in Group P. Another side
effect of tramadol, perspiration, was observed more
frequently in Group T than in Group P. This may be
attributed to the significantly higher dose of tra-
madol in Group T.
Previous studies have shown that tramadol is asso-
ciated with a lower risk for sedation and dependency
than traditional opioids. This was claimed to be due
to its weak affinity and potency for μ receptors, block-
ade of noradrenalin reuptake, and its slow onset of
action [28,35]. The Ramsey sedation scale was used to
measure the level of sedation in this study and the
scores were similar in both groups. Notably, an in-
crease in sedation did not occur in any patient. Thus,
the treatments used in both groups did not increase
sedation. The patients’ postanesthesia levels were as-
sessed using the Aldrete postanesthesia score. No sig-
nificant difference was found between the two groups
in terms of Aldrete score and the time needed to reach
an Aldrete score 9. Thus, the postanesthesia levels were
not prolonged in any patient.
A study on the use of propacetamol and ketorolac
in addition to PCA morphine in gynecology patients
showed no significant difference in patient satisfac-
tion levels between the two groups [36]. Similarly, there
was no difference in the number of patients who re-
ported their satisfaction with the pain treatment at 
24 hours as “very good” or “good” in our study. Thus,
the PCA method, which allows active patient manage-
ment of analgesia, is an effective control method that
requires lower drug doses, alleviates patient fear of
pain and gives patients the confidence that pain can
be relieved without depending on clinical staff.
Controlling the cost of analgesia is very important,
because the prices of new analgesic agents are gener-
ally high [37]. However, few studies have compared
the cost of tramadol versus low dose tramadol-parac-
etamol for postoperative PCA. In our study, we found
that the cost of low-dose tramadol-paracetamol was
higher than that of tramadol alone. However, the
costs of anesthesia may differ between countries and
may even vary in the same country over time, which
should be considered [37].
In conclusion, we compared low-dose PCA tra-
madol-paracetamol with tramadol for pain control
after spinal vertebral surgery. We found that low-
dose tramadol-paracetamol decreased the amount
and increased the effectiveness of analgesics admin-
istered in the postoperative period. This combination
reduced the incidence of side effects and provided ef-
fective analgesia. The combined paracetamol-tramadol
regimen was superior to tramadol alone in reducing
the intensity of pain during the 1st hour of treatment.
The cardiovascular, respiratory and postanesthesia
effects of tramadol and paracetamol-tramadol were
similar. Taken together, the PCA paracetamol-tramadol
combination regimen could be used safely for post-
operative pain management after spinal vertebral sur-
gery. However, the cost of the paracetamol-tramadol
combination was higher than that of tramadol alone.
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